Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Thermo Fisher Scientific

Thermo Fisher Scientific Raises $200B in Public

168 Third Avenue, Waltham, MA 02451January 1, 20242 min read
Employees
130000+

Thermo Fisher Scientific Raises $200B in Public


Thermo Fisher Scientific has successfully raised $200B in a Public at a $220B valuation led by Public.


Company Overview


Thermo Fisher Scientific is a Life Sciences company headquartered in 168 Third Avenue, Waltham, MA 02451, founded in 1956 with 130000+ employees.


Scientific instrumentation company


Fundraising Details


  • Amount Raised: $200B
  • Round Type: Public
  • Valuation: $220B
  • Date: 2024-01-01
  • Investors: Public

About Thermo Fisher Scientific


Scientific instrumentation company The company is positioned in the Life Sciences sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 168 Third Avenue, Waltham, MA 02451
  • Founded: 1956
  • Team Size: 130000+
  • Industry: Life Sciences

What This Means


This funding round demonstrates strong investor confidence in Thermo Fisher Scientific's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Life Sciences sector continues to attract significant investment as companies innovate to meet evolving market demands. Thermo Fisher Scientific's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $220B valuation marks an important milestone for Thermo Fisher Scientific, positioning the company among notable players in the Life Sciences industry.


Looking Ahead


With this new capital, Thermo Fisher Scientific is well-positioned to execute on its growth strategy and continue building innovative solutions in the Life Sciences space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Thermo Fisher Scientific, visit their headquarters at 168 Third Avenue, Waltham, MA 02451.

Company Info

Headquarters
168 Third Avenue, Waltham, MA 02451
Founded
1956
Team Size
130000+

Topics

Fundraising(2912)Public(771)Life SciencesThermo Fisher Scientific

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free